Lundbeck, Otsuka collborate on Alzheimer's

Share this article:

Lundbeck and Otsuka are working together on a vaccine to combat Alzheimer's disease. This would be the duo's third Alzheimer's collaboration, and the agreement tethers the companies through Phase I.

This effort is an anti-beta amyloid vaccine that the companies expect would be used in the elderly. The companies said in a statement that the idea behind the treatment is that it could preserve cognitive function by preventing amyloid-beta deposits from accumulating.

The companies will decide next steps when Phase I ends. They expect the study to start next year.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions